Abstract:
:As the variety and range of pharmaceutical agents available to the medical profession continues to expand, one unavoidable effect will be an increase in drug-induced disease, including cardiovascular disorders. However, given the high rates of cardiovascular disease and prevalence of recognised cardiovascular risk factors in the population, it is sometimes impossible to conclusively attribute any individual patients' ill health to one particular drug. As a result, the relationship between drugs and cardiovascular disease is often difficult to quantify. This review discusses specific forms of drug-induced cardiovascular disease such as heart failure, left ventricular systolic dysfunction, hypertension and arrhythmia. Suspected culprit drugs for all disorders are highlighted. Specific attention is given to certain drug groups with a strong association with one or more forms of cardiovascular disease: these include anthracyclines, antipsychotics, NSAIDs and cyclo-oxygenase 2 inhibitors. Additionally, advice is offered on how physicians might distinguish drug-induced cardiovascular disorders from other aetiologies.
journal_name
Drug Safjournal_title
Drug safetyauthors
Murphy CA,Dargie HJdoi
10.2165/00002018-200730090-00005subject
Has Abstractpub_date
2007-01-01 00:00:00pages
783-804issue
9eissn
0114-5916issn
1179-1942pii
3095journal_volume
30pub_type
杂志文章,评审相关文献
DRUG SAFETY文献大全abstract:BACKGROUND:In November 2009, a vaccination campaign against Influenza A (H1N1) was started in the Netherlands. The accelerated registration procedure of the vaccines used in this campaign and the use of these vaccines on a large scale indicated a need for real-time safety monitoring. OBJECTIVE:To describe the processi...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11539270-000000000-00000
更新日期:2010-12-01 00:00:00
abstract::Cholinesterase inhibitors are currently the most established treatment strategy in Alzheimer's disease. The treatment effect appears mainly to be symptomatic. Effects on progression of the disease following long term treatment, and possible neuroprotective effects, have been investigated. Delay until nursing home plac...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199819060-00004
更新日期:1998-12-01 00:00:00
abstract::The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-014-0189-0
更新日期:2014-08-01 00:00:00
abstract:INTRODUCTION:Previously, an app has been developed for healthcare professionals (HCPs) and patients to report adverse drug reactions (ADRs) to national medicines agencies and to receive drug safety information. OBJECTIVE:This study aimed to assess (1) European HCPs' and patients' interest in an app for this two-way ri...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-018-0648-0
更新日期:2018-07-01 00:00:00
abstract::Current key challenges and controversies encountered in the identification of potentially hepatotoxic drugs and the assessment of drug-induced liver injury (DILI) are covered in this article. There is substantial debate over the classification of DILI itself, including the definition and validity of terms such as 'int...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/BF03261997
更新日期:2012-12-01 00:00:00
abstract::Misoprostol, a prostaglandin E(1) analogue, is widely used in the US and other countries for cervical ripening and labour induction. Its use for these indications is not approved by the US Food and Drug Administration (FDA). The manufacturer of misoprostol issued a letter to American healthcare providers in August 200...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200225090-00005
更新日期:2002-01-01 00:00:00
abstract::Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic options of cardiovascular diseases with recognized clinical and epidemiological impact, such as non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE), and also in the preventive setting of orthopedic surgical pat...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-016-0464-3
更新日期:2016-12-01 00:00:00
abstract::Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. The ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-017-0590-6
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Individual case reports of suspected harm from medicines are fundamental for signal detection in postmarketing surveillance. Their effective analysis requires reliable data and one challenge is report duplication. These are multiple unlinked records describing the same suspected adverse drug reaction (ADR) i...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-014-0146-y
更新日期:2014-04-01 00:00:00
abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-019-00831-4
更新日期:2019-09-01 00:00:00
abstract:INTRODUCTION:An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs an...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-015-0297-5
更新日期:2015-08-01 00:00:00
abstract::Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-n...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-018-0760-1
更新日期:2019-05-01 00:00:00
abstract:BACKGROUND:Atypical antipsychotics have been associated with metabolic abnormalities including impaired glucose metabolism, exacerbation of existing diabetes mellitus and new-onset type 2 diabetes. Not all atypical antipsychotic agents appear to have the same propensity to cause these complications. OBJECTIVE:To asses...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200730070-00004
更新日期:2007-01-01 00:00:00
abstract:OBJECTIVES:A prescription event monitoring (PEM) postmarketing surveillance study was carried out to examine the safety of zafirlukast as used in general practice in England. METHODS:Exposure data were obtained from the first National Health Service (NHS) prescription dispensed for patients whose prescription details ...
journal_title:Drug safety
pub_type: 临床试验,杂志文章
doi:10.2165/00002018-200730050-00005
更新日期:2007-01-01 00:00:00
abstract::The WHO World Alliance on Patient Safety is a new, all encompassing project to improve medical care. Individual patients are the focus and all countries are encouraged to develop systems in which medical error, therapeutic accidents and failures are minimised. The potential for adverse events is present at all levels ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200528050-00002
更新日期:2005-01-01 00:00:00
abstract::The occurrence of breast cancer during pregnancy is a rare clinical situation. However, if it is diagnosed, a multidisciplinary approach involving an obstetrician, a medical oncologist and a surgeon is needed. In this situation, breast cancer should be treated according to the same principles applied in nonpregnant pa...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199818020-00005
更新日期:1998-02-01 00:00:00
abstract:BACKGROUND:Case reports have related the use of HMG-CoA reductase inhibitors ('statins') to Parkinson's disease (PD). Paradoxically, however, statins may have potentially beneficial effects on neurodegenerative diseases due to their anti-inflammatory properties. OBJECTIVE:To explore the risk of the development of PD i...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200831050-00004
更新日期:2008-01-01 00:00:00
abstract::Current antiretroviral therapy has lead to longer survival in patients infected with HIV, but it is also associated with new and important problems. Body fat redistribution and metabolic abnormalities, the so-called lipodystrophy syndrome, are among the most prevalent and worrisome ones. While an increasing number of ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200124030-00001
更新日期:2001-01-01 00:00:00
abstract:OBJECTIVE:During proton pump inhibitor (PPI) use, in clinical trials, headache is one of the most frequently reported adverse events (frequency 1.3 to 8.8%), while results of one observational study indicate that headache is the fifth most frequently reported adverse event (incidence densities 2.5 to 4.6 per 1000 patie...
journal_title:Drug safety
pub_type: 临床试验,杂志文章
doi:10.2165/00002018-200225040-00005
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:Spontaneous reporting of adverse drug reactions (ADRs) is fundamental to drug safety surveillance (pharmacovigilance); however, substantial under-reporting exists and is the main limitation of the system. Several factors could favour under-reporting. OBJECTIVE:The aim of this pilot study was to assess the e...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11319170-000000000-00000
更新日期:2010-05-01 00:00:00
abstract:BACKGROUND:Although systems to collect information about suspected adverse drug reactions (ADRs) were established in many countries and by the WHO in the 1960s, few studies have examined reported ADRs related to national income. OBJECTIVE:The aim of the study was to characterize ADRs reported to the WHO-ADR database, ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/BF03262002
更新日期:2012-12-01 00:00:00
abstract::Review of the medical records of 2 major adult teaching hospitals for a 4-year period revealed 33 instances of carbamazepine overdose. These patients had a mean age of 30 years and 58% were known epileptics. They ingested a mean of 12g carbamazepine (range 1.6 to 45g), with 51% of cases involving other drugs, particul...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199308010-00010
更新日期:1993-01-01 00:00:00
abstract:BACKGROUND:The tumour necrosis factor-alpha inhibitor infliximab is incorporated in the treatment guidelines for patients with inflammatory bowel disease (IBD). However, concerns about serious adverse events such as infections, malignancies and death do exist. OBJECTIVE:To evaluate the occurrence of serious events of ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/0002018-200831120-00009
更新日期:2008-01-01 00:00:00
abstract:INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-018-00786-y
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:Current pharmacosurveillance methods do not provide timely information on drug safety and effectiveness. Real-time surveillance using electronic prescribing systems could address this problem; however, the data collected using these systems has not been validated. We investigated the accuracy of using orders...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200831110-00005
更新日期:2008-01-01 00:00:00
abstract::NSAIDs are widely used to treat pain and inflammation in osteoarthritis. Their use in this indication is generally intermittent and fluctuates with the intensity of the disease. Nonetheless, success of the therapy is frequently limited by injury to the gastrointestinal mucosa and complications such as bleeding, ulcera...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200427030-00003
更新日期:2004-01-01 00:00:00
abstract::The prevalence and incidence of adverse drug interactions involving nonsteroidal anti-inflammatory drugs (NSAIDs) remains unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/or commonly coprescribed drugs, interac...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199308020-00002
更新日期:1993-02-01 00:00:00
abstract:INTRODUCTION:Checkpoint inhibitor drugs including ipilimumab have been reported to induce intestinal injury. OBJECTIVE:We aimed to evaluate the risk of chronic (> 6 weeks) enterocolitis following ipilimumab administration, and the likelihood that an enteritis vs colitis or enterocolitis is seen. PATIENTS AND METHODS:...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-020-00979-4
更新日期:2020-12-01 00:00:00
abstract::The last decade has seen an increase in the trend of HMG-CoA reductase inhibitor (statin) usage in the Western world, which does not come as a surprise noting that the latest American Heart Association heart and stroke statistics indicate an alarming prevalence of 80 million Americans (one in three) with one or more ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/11584380-000000000-00000
更新日期:2011-01-01 00:00:00
abstract:OBJECTIVES:Difficulty sleeping is a recognised tobacco withdrawal symptom, but sleep problems, like application site reactions, are commonly reported as adverse reactions to transdermal nicotine therapy. However, no studies have examined potential predictive factors associated with the occurrence of expected adverse ex...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-199920060-00007
更新日期:1999-06-01 00:00:00